# Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer

> **NCT00423917** · PHASE2 · COMPLETED · sponsor: **Alliance for Clinical Trials in Oncology** · enrollment: 36 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **BIOLOGICAL:** bevacizumab
- **DRUG:** fulvestrant

## Key facts

- **NCT ID:** NCT00423917
- **Lead sponsor:** Alliance for Clinical Trials in Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2009-02
- **Final completion:** 2017-01-15
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2018-05-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00423917

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00423917, "Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00423917. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*